Autopsy report · NCT00504101

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

“Temporarily closed to accrual pending availablity of drug.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

University of Miami

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

Arsenic trioxide; Bortezomib; Melphalan; Autologous hematopoietic stem cell transplantation

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
  “Closed due to lack of drug availability.” (74% match in meaning)
• A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer
  “Closed due to slow patient accrual.” (70% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (66% match in meaning)
• Exenatide For Reducing the Reinforcing Effects of Cocaine
  “The study was closed due to the inability to acquire the study drug.” (65% match in meaning)
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  “Drug no longer available” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.